218 related articles for article (PubMed ID: 25399279)
1. Fixed-dose combination therapy (polypill) for the prevention of cardiovascular disease.
Huffman MD; de Cates AN; Ebrahim S
JAMA; 2014 Nov; 312(19):2030-1. PubMed ID: 25399279
[TBL] [Abstract][Full Text] [Related]
2. Fixed-dose combination therapy for the prevention of cardiovascular disease.
de Cates AN; Farr MR; Wright N; Jarvis MC; Rees K; Ebrahim S; Huffman MD
Cochrane Database Syst Rev; 2014 Apr; 4(4):CD009868. PubMed ID: 24737108
[TBL] [Abstract][Full Text] [Related]
3. Impact of switching from different treatment regimens to a fixed-dose combination pill (polypill) in patients with cardiovascular disease or similarly high risk.
Lafeber M; Spiering W; Visseren FL; Grobbee DE; Bots ML; Stanton A; Patel A; Prabhakaran D; Webster R; Thom S; Rodgers A;
Eur J Prev Cardiol; 2017 Jun; 24(9):951-961. PubMed ID: 28436727
[TBL] [Abstract][Full Text] [Related]
4. A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk.
Patel A; Cass A; Peiris D; Usherwood T; Brown A; Jan S; Neal B; Hillis GS; Rafter N; Tonkin A; Webster R; Billot L; Bompoint S; Burch C; Burke H; Hayman N; Molanus B; Reid CM; Shiel L; Togni S; Rodgers A;
Eur J Prev Cardiol; 2015 Jul; 22(7):920-30. PubMed ID: 24676715
[TBL] [Abstract][Full Text] [Related]
5. The Effect of a Cardiovascular Polypill Strategy on Pill Burden.
Truelove M; Patel A; Bompoint S; Brown A; Cass A; Hillis GS; Peiris D; Rafter N; Reid CM; Rodgers A; Tonkin A; Usherwood T; Webster R;
Cardiovasc Ther; 2015 Dec; 33(6):347-52. PubMed ID: 26280247
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial.
Roshandel G; Khoshnia M; Poustchi H; Hemming K; Kamangar F; Gharavi A; Ostovaneh MR; Nateghi A; Majed M; Navabakhsh B; Merat S; Pourshams A; Nalini M; Malekzadeh F; Sadeghi M; Mohammadifard N; Sarrafzadegan N; Naemi-Tabiei M; Fazel A; Brennan P; Etemadi A; Boffetta P; Thomas N; Marshall T; Cheng KK; Malekzadeh R
Lancet; 2019 Aug; 394(10199):672-683. PubMed ID: 31448738
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of a fixed dose combination (polypill) in secondary prevention of cardiovascular diseases in India: Within-trial cost-effectiveness analysis of the UMPIRE trial.
Singh K; Crossan C; Laba TL; Roy A; Hayes A; Salam A; Jan S; Lord J; Tandon N; Rodgers A; Patel A; Thom S; Prabhakaran D
Int J Cardiol; 2018 Jul; 262():71-78. PubMed ID: 29622506
[TBL] [Abstract][Full Text] [Related]
8. Impact of polypill difficult to demonstrate from varied studies, say Cochrane reviewers.
Torjesen I
BMJ; 2014 Apr; 348():g2819. PubMed ID: 24742603
[No Abstract] [Full Text] [Related]
9. Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial.
Thom S; Poulter N; Field J; Patel A; Prabhakaran D; Stanton A; Grobbee DE; Bots ML; Reddy KS; Cidambi R; Bompoint S; Billot L; Rodgers A;
JAMA; 2013 Sep; 310(9):918-29. PubMed ID: 24002278
[TBL] [Abstract][Full Text] [Related]
10. The evening versus morning polypill utilization study: the TEMPUS rationale and design.
Lafeber M; Grobbee DE; Bots ML; Thom S; Webster R; Rodgers A; Visseren FL; Spiering W
Eur J Prev Cardiol; 2014 Apr; 21(4):425-33. PubMed ID: 23382539
[TBL] [Abstract][Full Text] [Related]
11. Polypill with or without Aspirin in Persons without Cardiovascular Disease.
Yusuf S; Joseph P; Dans A; Gao P; Teo K; Xavier D; López-Jaramillo P; Yusoff K; Santoso A; Gamra H; Talukder S; Christou C; Girish P; Yeates K; Xavier F; Dagenais G; Rocha C; McCready T; Tyrwhitt J; Bosch J; Pais P;
N Engl J Med; 2021 Jan; 384(3):216-228. PubMed ID: 33186492
[TBL] [Abstract][Full Text] [Related]
12. The concept of the polypill in the prevention of cardiovascular disease.
Wiley B; Fuster V
Ann Glob Health; 2014; 80(1):24-34. PubMed ID: 24751562
[TBL] [Abstract][Full Text] [Related]
13. A polypill for all? Critical review of the polypill literature for primary prevention of cardiovascular disease and stroke.
Carey KM; Comee MR; Donovan JL; Kanaan AO
Ann Pharmacother; 2012 May; 46(5):688-95. PubMed ID: 22570437
[TBL] [Abstract][Full Text] [Related]
14. One pill, four questions: what we still need to know about reducing cardiovascular risk with combination therapy.
Hughes AD
Cochrane Database Syst Rev; 2014 Apr; 2014(4):ED000079. PubMed ID: 24818243
[No Abstract] [Full Text] [Related]
15. Prevention: Polypills for cardiovascular prevention: a step forward?
Sanz G; Fuster V
Nat Rev Cardiol; 2013 Dec; 10(12):683-4. PubMed ID: 24101102
[TBL] [Abstract][Full Text] [Related]
16. The combined use of aspirin, a statin, and blood pressure-lowering agents (polypill components) and the risk of vascular morbidity and mortality in patients with coronary artery disease.
Lafeber M; Spiering W; van der Graaf Y; Nathoe H; Bots ML; Grobbee DE; Visseren FL
Am Heart J; 2013 Aug; 166(2):282-289.e1. PubMed ID: 23895811
[TBL] [Abstract][Full Text] [Related]
17. Combined use of polypill components in patients with type 2 diabetes mellitus.
Janssen VE; Visseren FL; de Boer A; Grobbee DE; Westerink J; van der Graaf Y; Lafeber M;
Eur J Prev Cardiol; 2018 Sep; 25(14):1523-1531. PubMed ID: 30033753
[TBL] [Abstract][Full Text] [Related]
18. Improving cardiovascular protection: focus on a cardiovascular polypill.
Barrios V; Escobar C
Future Cardiol; 2016 Mar; 12(2):181-96. PubMed ID: 26652213
[TBL] [Abstract][Full Text] [Related]
19. A pilot double-blind randomised placebo-controlled trial of the effects of fixed-dose combination therapy ('polypill') on cardiovascular risk factors.
Malekzadeh F; Marshall T; Pourshams A; Gharravi M; Aslani A; Nateghi A; Rastegarpanah M; Khoshnia M; Semnani S; Salahi R; Thomas GN; Larijani B; Cheng KK; Malekzadeh R
Int J Clin Pract; 2010 Aug; 64(9):1220-7. PubMed ID: 20653798
[TBL] [Abstract][Full Text] [Related]
20. Estimated cardiovascular relative risk reduction from fixed-dose combination pill (polypill) treatment in a wide range of patients with a moderate risk of cardiovascular disease.
Lafeber M; Webster R; Visseren FLj; Bots ML; Grobbee DE; Spiering W; Rodgers A;
Eur J Prev Cardiol; 2016 Aug; 23(12):1289-97. PubMed ID: 26743587
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
